# TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA.

> **NCT05233098** · — · COMPLETED · sponsor: **Boston Scientific Corporation** · enrollment: 6 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DEVICE:** Technetium-99m macroaggregated albumin (Tc-99m MAA)

## Key facts

- **NCT ID:** NCT05233098
- **Lead sponsor:** Boston Scientific Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-04
- **Primary completion:** 2023-06-14
- **Final completion:** 2023-06-14
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05233098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05233098, "TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05233098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*